Prognostic impact of conversion surgery in patients with stage IV gastric cancer: A multicenter population-based cohort study

IF 2.4 4区医学 Q3 ONCOLOGY

Surgical Oncology-Oxford Pub Date : 2025-05-23 DOI:10.1016/j.suronc.2025.102241

Hirohito Kakinuma , Michitaka Honda , Hidetaka Kawamura , Soshi Hori , Teppei Miyakawa , Satoshi Toshiyama , Yoshinao Takano , Shunji Kinuta , Takahiro Kamiga , Satoru Shiraso , Koji Kono

{"title":"Prognostic impact of conversion surgery in patients with stage IV gastric cancer: A multicenter population-based cohort study","authors":"Hirohito Kakinuma , Michitaka Honda , Hidetaka Kawamura , Soshi Hori , Teppei Miyakawa , Satoshi Toshiyama , Yoshinao Takano , Shunji Kinuta , Takahiro Kamiga , Satoru Shiraso , Koji Kono","doi":"10.1016/j.suronc.2025.102241","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The efficacy of conversion surgery (CS) for stage IV advanced gastric cancer (AGC) remains unclear. This study aimed to provide an overview of the clinical practice for Stage IV AGC and to evaluate the effectiveness of CS.</div></div><div><h3>Methods</h3><div>This is a retrospective cohort study. Consecutive patients diagnosed with stage IV AGC between 2008 and 2015 at designated cancer hospitals in Fukushima Prefecture, Japan, were enrolled in this study. We evaluated the relationship between CS and survival time and calculated the adjusted hazard ratios of CS for overall survival.</div></div><div><h3>Results</h3><div>A total of 647 patients were enrolled. CS was performed in 57 (8.8 %) patients. The CS group had fewer metastatic lesions (p = 0.01) and fewer liver metastases (p < 0.01) relative to the non-CS group. The adjusted hazard ratios of CS for overall survival were 0.34 (95 % confidence interval: 0.24–0.48, p < 0.01). The median survival time was 28.0 months in the CS group and 8.2 months in the non-CS group.</div></div><div><h3>Conclusion</h3><div>This study revealed the implementation status of CS for patients with stage IV AGC. CS may improve the patient prognosis.</div></div>","PeriodicalId":51185,"journal":{"name":"Surgical Oncology-Oxford","volume":"61 ","pages":"Article 102241"},"PeriodicalIF":2.4000,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgical Oncology-Oxford","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0960740425000568","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The efficacy of conversion surgery (CS) for stage IV advanced gastric cancer (AGC) remains unclear. This study aimed to provide an overview of the clinical practice for Stage IV AGC and to evaluate the effectiveness of CS.

Methods

This is a retrospective cohort study. Consecutive patients diagnosed with stage IV AGC between 2008 and 2015 at designated cancer hospitals in Fukushima Prefecture, Japan, were enrolled in this study. We evaluated the relationship between CS and survival time and calculated the adjusted hazard ratios of CS for overall survival.

Results

A total of 647 patients were enrolled. CS was performed in 57 (8.8 %) patients. The CS group had fewer metastatic lesions (p = 0.01) and fewer liver metastases (p < 0.01) relative to the non-CS group. The adjusted hazard ratios of CS for overall survival were 0.34 (95 % confidence interval: 0.24–0.48, p < 0.01). The median survival time was 28.0 months in the CS group and 8.2 months in the non-CS group.

Conclusion

This study revealed the implementation status of CS for patients with stage IV AGC. CS may improve the patient prognosis.

查看原文本刊更多论文

转化手术对IV期胃癌患者预后的影响：一项多中心人群队列研究

背景：IV期晚期胃癌（AGC）转化手术（CS）的疗效尚不清楚。本研究旨在概述IV期AGC的临床实践，并评估CS的有效性。方法回顾性队列研究。本研究纳入了2008 - 2015年在日本福岛县指定癌症医院连续诊断为IV期AGC的患者。我们评估了CS与生存时间之间的关系，并计算了CS对总生存的校正风险比。结果共纳入647例患者。57例（8.8%）患者行CS。CS组转移灶较少（p = 0.01），肝转移灶较少(p <；0.01)，相对于非cs组。CS对总生存率的校正风险比为0.34(95%置信区间：0.24-0.48,p <；0.01)。CS组中位生存时间为28.0个月，非CS组中位生存时间为8.2个月。结论本研究揭示了IV期AGC患者CS的实施情况。CS可改善患者预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Surgical Oncology-Oxford 医学-外科

CiteScore

4.50

自引率

0.00%

发文量

169

审稿时长

38 days

期刊介绍： Surgical Oncology is a peer reviewed journal publishing review articles that contribute to the advancement of knowledge in surgical oncology and related fields of interest. Articles represent a spectrum of current technology in oncology research as well as those concerning clinical trials, surgical technique, methods of investigation and patient evaluation. Surgical Oncology publishes comprehensive Reviews that examine individual topics in considerable detail, in addition to editorials and commentaries which focus on selected papers. The journal also publishes special issues which explore topics of interest to surgical oncologists in great detail - outlining recent advancements and providing readers with the most up to date information.